Five, seven or ten? No – it’s not a trendy store for juniors… it is a real-life anti-estrogen treatment dilemma facing oncologists and their post-menopausal, ER+, early-stage, breast cancer patients. Standard of care is to take anti-estrogen treatment for at least the first 5 years after diagnosis to help prevent hormone-receptor positive breast cancer recurrences.
The world’s best-known breast cancer experts weigh in on issues related to ER+ early stage breast cancer – Part 1
In a consensus report published last week, Endocrine therapy and related issues in hormone receptor‑positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG), the BCTEG addressed four gaps in current guidance for oncologists related to the most common form of breast cancer, estrogen receptor positive (ER+) early stage breast …
Last week marked another busy and exciting few days at the 2016 San Antonio Breast Cancer Symposium (SABCS), a five-day conference geared toward an international community of more than 7,000 physicians, researchers, and advocates. The purpose of the annual meeting is to share and discuss data and insights from groundbreaking research on breast cancer biology, … Continue reading Highlights from the San Antonio Breast Cancer Symposium (SABCS)